Ricrisa Pharmaceuticals Private Limited
About Ricrisa Pharmaceuticals Private Limited
Data last updated:
Ricrisa Pharmaceuticals Private Limited is a private limited company based in Nagpur, Maharashtra, India. It operates in the manufacturing segment of the chemicals sector. It was incorporated on 04 January 2022.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24230MH2022PTC374333.
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors including Rupali Rahul Kondalkar and Sneha Shyamkant Suryawanshi.
Its last annual general meeting (AGM) was held on 24 November 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 802 Balaji Nagar Hingna Nagpur Digdoh, Maharashtra, India – 441110.
As per the financials filed for FY 2025, the company reported a revenue of ₹9.91 Lakh, a growth of 43% compared to the previous year. For the same year it recorded a net profit of ₹10,100 (net margin 1%) and EBITDA of ₹10,100 (EBITDA margin 1%). Revenue has grown at a compounded annual rate (CAGR) of 136% over three years.
Company details
Contact details
Ricrisa Pharmaceuticals Private Limited's registered office is in Nagpur, Maharashtra.
- Registered Address802 Balaji Nagar Hingna Nagpur Digdoh, Maharashtra, India – 441110
- IndustryChemicals, Manufacturing, Other Chemical Product
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Ricrisa Pharmaceuticals is wholesale and retail trade; repair of motor vehicles and motorcycles. In detail, this covers retail trade, except of motor vehicles and motorcycles.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Wholesale and retail trade; repair of motor vehicles and motorcycles | 47 | Retail trade, except of motor vehicles and motorcycles |
To see the full business activity and turnover split of Ricrisa Pharmaceuticals Private Limited, buy the company report.
Financials of Ricrisa Pharmaceuticals Private Limited
FY 2025 filings availableRicrisa Pharmaceuticals Private Limited reported revenue of ₹9.91 Lakh (up 43% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 136% over three years, including 43% growth in the latest year. EBITDA rose 110% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|
| Profit and Loss Statement | ||||
| Revenue from Operations | ||||
| Other Income | ||||
| Total Revenue | ||||
| Cost of Materials Consumed | ||||
| Employee Benefit Expense | ||||
| Finance Costs | ||||
| Depreciation and Amortisation | ||||
| Other Expenses | ||||
| Total Expenses | ||||
| EBITDA | ₹10,100 | |||
| Profit Before Tax | ||||
| Tax Expense | ||||
| Net Profit (PAT) | ₹10,100 | |||
| Balance Sheet | ||||
| Share Capital | ||||
| Reserves and Surplus | ||||
| Net Worth (Total Equity) | ||||
| Long-term Borrowings | ||||
| Short-term Borrowings | ||||
| Trade Payables | ||||
| Total Liabilities | ||||
| Fixed Assets | ||||
| Investments | ||||
| Inventories | ||||
| Trade Receivables | ||||
| Cash and Bank Balance | ||||
| Total Assets | ||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|
| Profitability | ||||
| EBITDA Margin | 1% | |||
| Net Profit Margin | 1% | |||
| Return on Equity (ROE) | ||||
| Return on Capital Employed (ROCE) | ||||
| Return on Assets (ROA) | ||||
| Liquidity and Debt | ||||
| Current Ratio | ||||
| Quick Ratio | ||||
| Debt-to-Equity Ratio | ||||
| Interest Coverage Ratio | ||||
| Efficiency and Growth | ||||
| Asset Turnover | ||||
| Receivable Days | ||||
| Payable Days | ||||
| Inventory Days | ||||
| Revenue Growth | ||||
| Net Profit Growth | ||||
To see the full financial statements and ratios of Ricrisa Pharmaceuticals Private Limited, buy the company report.
Board of directors of Ricrisa Pharmaceuticals Private Limited
Ricrisa Pharmaceuticals has 3 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rupali Rahul Kondalkar | Director | 04 Jan 2022 | 4 Years 10 Months | Current |
| Sneha Shyamkant Suryawanshi | Director | 04 Jan 2022 | 4 Years 10 Months | Current |
| Nitesh Madhukar Lad | Director | 04 Jan 2022 | 4 Years 10 Months | Current |
Legal cases
No court or tribunal cases involving Ricrisa Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Ricrisa Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Ricrisa Pharmaceuticals Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Ricrisa Pharmaceuticals Private Limited has 3 board changes on record since 2022: 3 appointments. The latest: Nitesh Madhukar Lad was appointed as Director on 04 Jan 2022.
Frequently asked questions
Ricrisa Pharmaceuticals is an active private limited company based in Nagpur, Maharashtra, India. The company works in manufacturing, within the chemicals industry. It was incorporated on 04 January 2022 (4+ years old) and is registered under CIN U24230MH2022PTC374333.
Ricrisa Pharmaceuticals has 3 current directors:
- Rupali Rahul Kondalkar - Director
- Sneha Shyamkant Suryawanshi - Director
- Nitesh Madhukar Lad - Director
The latest financial statements of Ricrisa Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 24 November 2025. Year-wise statements from FY 2022 are in the company report.
The CIN (Corporate Identification Number) of Ricrisa Pharmaceuticals is U24230MH2022PTC374333. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Ricrisa Pharmaceuticals was incorporated on 04 January 2022, making it 4+ years old. It is registered with the Registrar of Companies, Mumbai.
Nitesh Madhukar Lad was appointed as Director on 04 Jan 2022. Rupali Rahul Kondalkar was appointed as Director on 04 Jan 2022. Sneha Shyamkant Suryawanshi was appointed as Director on 04 Jan 2022.
The registered office of Ricrisa Pharmaceuticals is at 802 Balaji Nagar Hingna Nagpur Digdoh, Maharashtra, India – 441110.
Ricrisa Pharmaceuticals operates in the chemicals industry, in the manufacturing segment.
Ricrisa Pharmaceuticals can be reached at its registered office: 802 Balaji Nagar Hingna Nagpur Digdoh, Maharashtra, India – 441110.
Ricrisa Pharmaceuticals is registered under the jurisdiction of the Registrar of Companies (ROC), Mumbai.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
